Sharon Graw
Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 22 | 2026 | 357 | 2.540 |
Why?
| | Arrhythmias, Cardiac | 11 | 2026 | 358 | 0.930 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 6 | 2020 | 60 | 0.730 |
Why?
| | Cardiomyopathies | 5 | 2025 | 339 | 0.680 |
Why?
| | Filamins | 4 | 2025 | 28 | 0.670 |
Why?
| | Connectin | 8 | 2026 | 43 | 0.650 |
Why?
| | Ventricular Function, Left | 6 | 2025 | 541 | 0.620 |
Why?
| | Death, Sudden, Cardiac | 7 | 2025 | 242 | 0.600 |
Why?
| | Phenotype | 17 | 2025 | 3186 | 0.500 |
Why?
| | Ventricular Remodeling | 3 | 2026 | 283 | 0.420 |
Why?
| | Genes, BRCA1 | 2 | 2005 | 45 | 0.410 |
Why?
| | Myocardium | 6 | 2026 | 948 | 0.400 |
Why?
| | Heart Failure | 8 | 2026 | 2323 | 0.400 |
Why?
| | Glycogen Storage Disease Type IIb | 3 | 2025 | 27 | 0.390 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2025 | 214 | 0.380 |
Why?
| | Electrocardiography | 6 | 2025 | 666 | 0.380 |
Why?
| | Genetic Predisposition to Disease | 9 | 2026 | 2455 | 0.320 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 6 | 2016 | 94 | 0.300 |
Why?
| | Stroke Volume | 7 | 2025 | 651 | 0.280 |
Why?
| | RNA-Binding Proteins | 2 | 2026 | 463 | 0.280 |
Why?
| | Heart Ventricles | 4 | 2025 | 762 | 0.280 |
Why?
| | Receptors, Nicotinic | 4 | 2012 | 327 | 0.270 |
Why?
| | Founder Effect | 2 | 2005 | 13 | 0.270 |
Why?
| | Genetic Testing | 8 | 2025 | 491 | 0.270 |
Why?
| | Sequence Deletion | 3 | 2014 | 190 | 0.260 |
Why?
| | Myocytes, Cardiac | 4 | 2026 | 542 | 0.260 |
Why?
| | Mutation | 10 | 2020 | 4082 | 0.240 |
Why?
| | Iodide Peroxidase | 1 | 2026 | 34 | 0.230 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1790 | 0.230 |
Why?
| | Middle Aged | 28 | 2026 | 36359 | 0.230 |
Why?
| | DNA Mutational Analysis | 7 | 2018 | 409 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2025 | 45 | 0.220 |
Why?
| | Genetic Variation | 4 | 2021 | 992 | 0.220 |
Why?
| | Jews | 1 | 2005 | 18 | 0.220 |
Why?
| | Nanotubes, Carbon | 1 | 2025 | 47 | 0.210 |
Why?
| | Female | 43 | 2026 | 79080 | 0.210 |
Why?
| | Rare Diseases | 1 | 2025 | 115 | 0.210 |
Why?
| | RNA Splicing | 1 | 2026 | 287 | 0.210 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2025 | 124 | 0.210 |
Why?
| | Male | 39 | 2026 | 73014 | 0.210 |
Why?
| | Quantitative Trait Loci | 1 | 2026 | 388 | 0.200 |
Why?
| | Prognosis | 8 | 2025 | 4331 | 0.200 |
Why?
| | Muscle Proteins | 3 | 2025 | 242 | 0.200 |
Why?
| | Mutation, Missense | 3 | 2015 | 331 | 0.200 |
Why?
| | Alternative Splicing | 1 | 2026 | 249 | 0.200 |
Why?
| | Precision Medicine | 2 | 2026 | 462 | 0.190 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 199 | 0.190 |
Why?
| | Humans | 53 | 2026 | 145625 | 0.190 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2000 | 40 | 0.190 |
Why?
| | Adult | 26 | 2026 | 40821 | 0.190 |
Why?
| | Heart Rate | 2 | 2025 | 844 | 0.190 |
Why?
| | Genotype | 6 | 2025 | 1866 | 0.180 |
Why?
| | Germ-Line Mutation | 1 | 2003 | 180 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2022 | 63 | 0.170 |
Why?
| | Breast Neoplasms | 2 | 2005 | 2411 | 0.170 |
Why?
| | Biocompatible Materials | 1 | 2025 | 429 | 0.160 |
Why?
| | Gene Expression Regulation | 4 | 2026 | 2591 | 0.160 |
Why?
| | Tissue Engineering | 1 | 2025 | 439 | 0.160 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2016 | 144 | 0.160 |
Why?
| | Physical Chromosome Mapping | 1 | 2000 | 21 | 0.160 |
Why?
| | Chromosome Breakage | 1 | 2000 | 23 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 447 | 0.160 |
Why?
| | Chromosome Inversion | 1 | 2000 | 20 | 0.150 |
Why?
| | Protein Kinases | 2 | 2012 | 311 | 0.150 |
Why?
| | Heart-Assist Devices | 1 | 2026 | 570 | 0.150 |
Why?
| | Pedigree | 8 | 2015 | 507 | 0.150 |
Why?
| | Intellectual Disability | 1 | 2021 | 178 | 0.150 |
Why?
| | Ankyrins | 1 | 2019 | 11 | 0.150 |
Why?
| | Echocardiography | 4 | 2025 | 645 | 0.140 |
Why?
| | Mice, Inbred C3H | 3 | 2016 | 252 | 0.140 |
Why?
| | Recombination, Genetic | 1 | 2000 | 202 | 0.140 |
Why?
| | Cardiovascular Agents | 2 | 2025 | 165 | 0.140 |
Why?
| | Hippocampus | 2 | 2016 | 986 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2000 | 193 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2026 | 1212 | 0.130 |
Why?
| | Hydrogels | 1 | 2025 | 706 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2025 | 427 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2026 | 17291 | 0.130 |
Why?
| | Disease Management | 3 | 2021 | 649 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 211 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2003 | 598 | 0.130 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 4 | 0.120 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 27 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2018 | 277 | 0.120 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.120 |
Why?
| | Marfan Syndrome | 1 | 2017 | 44 | 0.120 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 286 | 0.120 |
Why?
| | Aged | 11 | 2026 | 26251 | 0.120 |
Why?
| | Transcriptome | 2 | 2020 | 1066 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2021 | 404 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 530 | 0.110 |
Why?
| | Lamin Type A | 3 | 2025 | 49 | 0.110 |
Why?
| | Genetic Association Studies | 3 | 2025 | 376 | 0.110 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2017 | 135 | 0.110 |
Why?
| | Registries | 6 | 2025 | 2382 | 0.110 |
Why?
| | Desmosomes | 1 | 2014 | 20 | 0.110 |
Why?
| | Spain | 2 | 2005 | 50 | 0.100 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 20 | 0.100 |
Why?
| | Base Sequence | 5 | 2014 | 2119 | 0.100 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 46 | 0.100 |
Why?
| | Long-Term Potentiation | 1 | 2016 | 206 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 186 | 0.100 |
Why?
| | Exons | 3 | 2025 | 361 | 0.100 |
Why?
| | Cohort Studies | 5 | 2026 | 6045 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2026 | 2228 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2014 | 176 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 6021 | 0.090 |
Why?
| | Heterozygote | 3 | 2025 | 310 | 0.090 |
Why?
| | Risk Assessment | 4 | 2025 | 3678 | 0.090 |
Why?
| | Mice, Knockout | 4 | 2026 | 3121 | 0.090 |
Why?
| | Genes, Duplicate | 1 | 2011 | 4 | 0.090 |
Why?
| | Schizophrenia | 3 | 2012 | 476 | 0.080 |
Why?
| | Colorado | 4 | 2017 | 4588 | 0.080 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2025 | 64 | 0.080 |
Why?
| | Neural Inhibition | 1 | 2012 | 180 | 0.080 |
Why?
| | Animals | 13 | 2026 | 38030 | 0.080 |
Why?
| | Organ Specificity | 2 | 2026 | 306 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 959 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 557 | 0.070 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2835 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2025 | 538 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 90 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1418 | 0.070 |
Why?
| | Time Factors | 4 | 2025 | 7079 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2025 | 771 | 0.060 |
Why?
| | Desmin | 1 | 2007 | 22 | 0.060 |
Why?
| | Biomarkers | 1 | 2018 | 4329 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1236 | 0.060 |
Why?
| | Cloning, Molecular | 3 | 2011 | 526 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 14240 | 0.060 |
Why?
| | Mice | 6 | 2026 | 18266 | 0.060 |
Why?
| | DNA Methylation | 1 | 2011 | 721 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 55 | 0.060 |
Why?
| | Neurons | 1 | 2015 | 1663 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2026 | 69 | 0.060 |
Why?
| | Syndrome | 2 | 2011 | 377 | 0.060 |
Why?
| | Ventricular Myosins | 1 | 2005 | 38 | 0.060 |
Why?
| | Risk Factors | 4 | 2025 | 10840 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1429 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5397 | 0.050 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 39 | 0.050 |
Why?
| | Injections | 1 | 2025 | 199 | 0.050 |
Why?
| | Introns | 1 | 2025 | 257 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 183 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2005 | 177 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 148 | 0.050 |
Why?
| | Aortic Diseases | 1 | 2025 | 124 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 441 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 48 | 0.050 |
Why?
| | Particle Size | 1 | 2025 | 382 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2015 | 777 | 0.050 |
Why?
| | Materials Testing | 1 | 2025 | 345 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2025 | 252 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2003 | 33 | 0.050 |
Why?
| | Karyotyping | 2 | 2000 | 106 | 0.050 |
Why?
| | Haplotypes | 1 | 2005 | 505 | 0.050 |
Why?
| | Disease Progression | 2 | 2025 | 2857 | 0.050 |
Why?
| | Genome, Human | 1 | 2025 | 425 | 0.050 |
Why?
| | DNA, Neoplasm | 1 | 2003 | 160 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2026 | 1526 | 0.050 |
Why?
| | Chromosome Mapping | 5 | 2009 | 505 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2019 | 5875 | 0.050 |
Why?
| | Chromosomes, Human, Pair 15 | 2 | 2015 | 50 | 0.050 |
Why?
| | Brain | 1 | 2015 | 2981 | 0.040 |
Why?
| | Temperature | 1 | 2025 | 633 | 0.040 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 269 | 0.040 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 179 | 0.040 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 2 | 2014 | 32 | 0.040 |
Why?
| | Microarray Analysis | 1 | 2021 | 117 | 0.040 |
Why?
| | Cell Line | 3 | 2009 | 2809 | 0.040 |
Why?
| | Recovery of Function | 1 | 2026 | 721 | 0.040 |
Why?
| | Chromosomes | 1 | 2021 | 105 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2021 | 167 | 0.040 |
Why?
| | Adolescent | 6 | 2025 | 22451 | 0.040 |
Why?
| | Cricetinae | 2 | 2000 | 295 | 0.040 |
Why?
| | Rats | 2 | 2026 | 5574 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 189 | 0.040 |
Why?
| | Terminal Repeat Sequences | 1 | 2000 | 17 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2018 | 3633 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2026 | 2533 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2000 | 126 | 0.040 |
Why?
| | Alu Elements | 1 | 2000 | 28 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2064 | 0.040 |
Why?
| | New Mexico | 1 | 2000 | 106 | 0.040 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2000 | 32 | 0.040 |
Why?
| | Maleimides | 1 | 2019 | 21 | 0.040 |
Why?
| | Atrial Fibrillation | 1 | 2025 | 559 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 192 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2005 | 1130 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2020 | 2783 | 0.040 |
Why?
| | Transfection | 3 | 2011 | 914 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2101 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 176 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1269 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 494 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 632 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2021 | 280 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11744 | 0.030 |
Why?
| | Alleles | 1 | 2021 | 900 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1467 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2021 | 560 | 0.030 |
Why?
| | Child | 4 | 2025 | 22638 | 0.030 |
Why?
| | Family Health | 2 | 2011 | 192 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 460 | 0.030 |
Why?
| | HeLa Cells | 2 | 2011 | 635 | 0.030 |
Why?
| | Family | 2 | 2014 | 680 | 0.030 |
Why?
| | Fibrosis | 1 | 2020 | 568 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 3005 | 0.030 |
Why?
| | beta Catenin | 1 | 2019 | 250 | 0.030 |
Why?
| | Europe | 1 | 2018 | 420 | 0.030 |
Why?
| | Aneurysm, False | 1 | 2017 | 45 | 0.030 |
Why?
| | Neck | 1 | 2017 | 107 | 0.030 |
Why?
| | Heredity | 1 | 2015 | 13 | 0.030 |
Why?
| | Sensory Gating | 1 | 2016 | 44 | 0.030 |
Why?
| | Italy | 1 | 2015 | 118 | 0.030 |
Why?
| | Head | 1 | 2017 | 125 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 151 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 196 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4565 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 509 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 542 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1994 | 5 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2016 | 322 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2852 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2011 | 269 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 495 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1994 | 116 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 1994 | 1030 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1993 | 36 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1709 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 317 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2011 | 3538 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.020 |
Why?
| | Cause of Death | 1 | 2015 | 455 | 0.020 |
Why?
| | Heart | 1 | 2017 | 624 | 0.020 |
Why?
| | Action Potentials | 1 | 2016 | 498 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1531 | 0.020 |
Why?
| | United States | 3 | 2018 | 16041 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2000 | 920 | 0.020 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 83 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 72 | 0.020 |
Why?
| | Penetrance | 1 | 2011 | 30 | 0.020 |
Why?
| | Bungarotoxins | 1 | 2011 | 45 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2000 | 6449 | 0.020 |
Why?
| | Xenopus laevis | 1 | 2011 | 101 | 0.020 |
Why?
| | Allosteric Regulation | 1 | 2011 | 100 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 402 | 0.020 |
Why?
| | Isoxazoles | 1 | 2011 | 56 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2011 | 58 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 172 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2112 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 675 | 0.020 |
Why?
| | Multigene Family | 1 | 2011 | 209 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2097 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2011 | 122 | 0.020 |
Why?
| | Point Mutation | 1 | 2011 | 232 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2011 | 288 | 0.020 |
Why?
| | Oocytes | 1 | 2011 | 186 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 973 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 676 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 679 | 0.020 |
Why?
| | Autistic Disorder | 1 | 2012 | 215 | 0.020 |
Why?
| | RNA | 2 | 2011 | 925 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 257 | 0.020 |
Why?
| | Child, Preschool | 2 | 2000 | 11888 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2088 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2910 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 31 | 0.020 |
Why?
| | Genes, Dominant | 1 | 2007 | 94 | 0.020 |
Why?
| | Epilepsy | 1 | 2012 | 397 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 705 | 0.020 |
Why?
| | Cognition | 1 | 2015 | 1286 | 0.010 |
Why?
| | Signal Transduction | 1 | 2020 | 5234 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2012 | 798 | 0.010 |
Why?
| | Mental Disorders | 1 | 2015 | 1133 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 403 | 0.010 |
Why?
| | Prospective Studies | 1 | 2018 | 8087 | 0.010 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 74 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2239 | 0.010 |
Why?
| | Sarcomeres | 1 | 2005 | 100 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2005 | 242 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2005 | 388 | 0.010 |
Why?
| | Smoking | 1 | 2011 | 1478 | 0.010 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 452 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 834 | 0.010 |
Why?
| | DNA Primers | 2 | 1994 | 487 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1461 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 391 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2007 | 4112 | 0.010 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1981 | 3 | 0.010 |
Why?
| | Carbon-Nitrogen Ligases | 1 | 1981 | 5 | 0.010 |
Why?
| | Ligases | 1 | 1981 | 38 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2005 | 1795 | 0.010 |
Why?
| | Muridae | 1 | 1994 | 6 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 1994 | 22 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1994 | 120 | 0.010 |
Why?
| | Cosmids | 1 | 1993 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1993 | 80 | 0.010 |
Why?
| | Genetic Markers | 1 | 1994 | 337 | 0.010 |
Why?
| | Infant | 1 | 2007 | 10093 | 0.010 |
Why?
| | Genome | 1 | 1994 | 307 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 47 | 0.000 |
Why?
| | Cell Fusion | 1 | 1981 | 47 | 0.000 |
Why?
| | Genetic Complementation Test | 1 | 1981 | 72 | 0.000 |
Why?
| | Cricetulus | 1 | 1981 | 115 | 0.000 |
Why?
| | Purines | 1 | 1981 | 188 | 0.000 |
Why?
| | Ovary | 1 | 1981 | 235 | 0.000 |
Why?
| | Lymphocytes | 1 | 1981 | 379 | 0.000 |
Why?
| | Fibroblasts | 1 | 1981 | 1033 | 0.000 |
Why?
|
|
Graw's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|